In October 2017, Incyte entered into a global collaboration and license agreement with us in which they obtained exclusive worldwide rights for the development and commercialization of MGA012 (retifanlimab), an anti-PD-1 antibody, in all indications.This molecule has received FDA approval and is marketed as ZYNYZ™. In addition to receiving an upfront payment, we are eligible to receive milestones and royalties and retains the right to develop our pipeline assets in combination with retifanlimab. Learn more
Collaborations have been a critical part of MacroGenics’ growth strategy and will continue to be an emphasis for our future growth strategy. To date, the company has developed significant alliances with leading pharmaceutical and biotechnology companies that enable us to drive our proprietary programs forward, while retaining significant value in the downstream potential of our partnered programs.
The company is actively exploring alliances that complement our expertise in biologics product development with important scientific, clinical and business capabilities. These alliances may incorporate our various technology platforms, product candidates and biologic product development capabilities.
Selected MacroGenics Collaboration Partners
Incyte Corporation
Gilead Sciences
In October 2022, we announced that Gilead entered into an exclusive option and collaboration agreement with us to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using our DART® platform, and two additional bispecific research programs. We are responsible for the ongoing Phase 1 study for MGD024 during which Gilead may elect to exercise its option to license the program at predefined decision points. We received an upfront payment and will be eligible to receive target nomination, option fees, and milestone payments. We will also be eligible to receive royalties on worldwide net sales of MGD024 and products under the two research programs. In September 2023, Gilead nominated the first of two research programs, leveraging our DART and TRIDENT® platforms for generating bispecific antibodies. This nomination granted Gilead an exclusive option, upon which achievement of a pre-defined preclinical milestone, to license worldwide rights to the research program. Learn more
Sanofi
In 2018, we entered into multiple agreements with Provention Bio, Inc. (acquired in 2023 by Sanofi) pursuant to which we granted exclusive global rights for the purpose of developing and commercializing MGD010 (PRV-3279), a CD32B x CD79B DART molecule, for the treatment of autoimmune indications. In addition, Provention acquired our interest in teplizumab, an anti-CD3 monoclonal antibody approved by the U.S. FDA in November 2022 as the first and only treatment to delay the onset of Stage 3 type 1 diabetes. Teplizumab is marketed by Sanofi as TZIELD®. In addition, in March 2023, we entered into an agreement to sell our royalty interest on future global net sales of TZIELD to a wholly-owned subsidiary of DRI Healthcare Trust for up to $200 million. We retained other economic interests related to TZIELD, including future potential regulatory and commercial milestones. Learn more
Tersera
In October 2024, we announced that we had entered into an agreement with TerSera Therapeutics, LLC, a privately-held biopharmaceutical company with a focus on oncology and non-opioid pain management, in which TerSera was to acquire global rights to MARGENZA® (margetuximab-cmkb), an Fc-optimized antibody developed by MacroGenics and approved by the U.S. FDA in December 2020 for the treatment, in combination with chemotherapy, for certain adult patients with metastatic HER2-positive breast cancer. In November 2024, the transaction closed; MacroGenics received an upfront payment and is eligible to receive additional sales milestone payments. MacroGenics will manufacture MARGENZA drug substance on behalf of TerSera going forward. Learn more